DETAILED ACTION
Claims 1-7 are pending in the instant application.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
The instant application claims priority to the U.S. Provisional Application Serial No. 63/600,121 filed 11/17/2023.
Claim Objections
Claims 2-4 are objected to because of the following informalities: “tabletted” should be corrected to “tableted”. Appropriate correction is required.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1 and 5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1 and 5 blur the metes and bounds of the claims due to words in parentheses. The examiner cannot determine if they are exemplary or limited to one or more of these terms.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over Pesaro et al. (WO 2020/043269 A1), Dussia et al. (WO 2009/052421 A1), Figueiredo et al. (Propolis, Aloe Vera, Green Tea, Cranberry, Calendula, Myrrha, and Salvia Properties against Periodontal Microorganisms, microorganisms, 2022), and Tiftikci et al. (WO 2022/108546 A1).
Pesaro discloses antimicrobial mixtures (Abstract). The formulation can be an effervescent preparation ([0083]). The composition can contain oils ([0028]), aloe vera ([0067]), shitake mushroom extract ([0063]), and green tea ([0062]). The preparation can be in the form of tablets ([0137]).
Pesaro does not teach cranberry used for dental treatment.
Dussia discloses compositions for administering an active ingredient orally or transmucosally having a film layer. The composition includes an effervescent compound (Abstract). An effervescent compound may include citric, tartaric and sodium bicarbonate ([0106]). The composition includes oil ([0109]), starches (corn, potato, rice, or tapioca) ([0093]), aloe vera ([0076]), shitake extract ([0058]), cranberry (claim 17). Cranberry is used to prevent or treat dental decay ([0065]). The composition can be in the form of a powder ([0004]). Dussia discloses that the film strip rapidly dissolved upon administration to the oral cavity ([0107]).
Figueiredo discloses that natural agent is aloe vera or Aloe barbadensis, which is a cactus-like succulent plant that belongs to the Liliaceae family. Cosmetic and medicinal products are made from the mucilaginous tissue in the center of the aloe vera leaf. Aloe vera is known to have several therapeutic benefits and has long been used as a remedy for various conditions such as sunburn, wounds, skin problems and digestive tract disorders. The pharmacological benefits of aloe vera are attributed to its wound-healing effects; immunomodulatory activity; and anti-inflammatory, antioxidant and antimicrobial properties (pg 6, 2nd paragraph). Green tea has been shown to combat microorganisms in various ways, directly and indirectly, and has worked synergistically with some antibiotic agents. Its anti-inflammatory and antioxidant effects may also contribute to the antimicrobial effect (pg 7, 1st paragraph). Cranberries are among some foods that contain type A proanthocyanidins, which have higher bioactivity compared to type B. Cranberry bioactive agents have unique characteristics, and modern science is trying to identify the connections between the health benefits and the specific compounds that this fruit has. Particularly in dentistry, proanthocyanidins are known to inhibit oral biofilm adherence and for their anti-inflammatory effect that could potentially be able to neutralize the destructive inflammatory response of macrophages (pg 7, 3rd paragraph).
Tiftikci discloses development of dental cleaning formulation in the form of effervescent tablet (Abstract). The production process generally includes the process of weighing each ingredient, passing each ingredient through a sieve, mixing ingredients, and pressing tablets (pg 6).
Therefore, it would have been obvious to one of ordinary person in the art before the effective filing date of the claimed invention to have combined teachings of above to create a tableted effervescing dental treatment composition. This is taking some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention.
Regarding claim 2, powder is taught above.
regarding claim 3, oral cavity disintegration is taught above.
Regarding claim 4, Tiftikci discloses that tablets weighed 450 mg on average. However, one of ordinary skill in the art would experiment with different tablet weights for consumers.
Regarding claim 5, a method of producing an effervescent tablet is taught above.
Regarding claim 6, Tiftikci discloses that the products can be easily transported due to different packaging sizes (pg 3, line 17).
Regarding claim 7, it would be obvious to one of ordinary skill in the art to have provided a composition comprising ingredients beneficial for dental treatment, for treating dental surfaces simultaneously reducing dental plaque.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN SEUNGJAI KWON whose telephone number is (571)272-7737. The examiner can normally be reached Mon - Fri 8:00 - 5:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A. Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JOHN SEUNGJAI KWON/Examiner, Art Unit 1615
/Robert A Wax/Supervisory Patent Examiner, Art Unit 1615